Beam Therapeutics (BEAM) Cash & Equivalents (2019 - 2026)

Beam Therapeutics (BEAM) has reported Cash & Equivalents for 8 consecutive years, with $288.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents fell 45.39% year-over-year to $288.3 million; the TTM figure through Mar 2026 stood at $288.3 million (down 45.39% YoY), while the FY2025 annual figure was $294.9 million, up 4.6% from the prior year.
• Cash & Equivalents eased to $288.3 million in Q1 2026 per BEAM's latest filing, from $294.9 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $527.9 million in Q1 2025 and bottomed at $156.5 million in Q3 2022.
• Historically, Cash & Equivalents has averaged $281.5 million across 5 years, with a median of $282.0 million in 2024.
• On a YoY basis, Cash & Equivalents climbed as much as 205.24% in 2022 and fell as far as 74.43% in 2022.
• Beam Therapeutics' Cash & Equivalents stood at $232.8 million in 2022, then jumped by 87.27% to $435.9 million in 2023, then slumped by 35.31% to $282.0 million in 2024, then climbed by 4.6% to $294.9 million in 2025, then fell by 2.26% to $288.3 million in 2026.
• Business Quant data shows BEAM's Cash & Equivalents at $288.3 million in Q1 2026, $294.9 million in Q4 2025, and $268.0 million in Q3 2025.